Investors Accuse Chelsea Of Overselling Drug's Potential
Investors filed a pair of proposed securities class actions in North Carolina federal court Wednesday accusing Chelsea Therapeutics International Ltd. of making false and misleading statements regarding the development of hypotension...To view the full article, register now.
Already a subscriber? Click here to view full article